Q-omics provides the consensus-scored FTLP19 profile across patient tissues and cancer cell-line models. FTLP19 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FTLP19 is differentially expressed in 3, with the highest sampling consensus in PAAD. Additionally, FTLP19 RNA expression shows 6,458 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UVM, PAAD, and STAD as cancer lineages where FTLP19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FTLP19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FTLP19 survival associations across molecular data types. FTLP19 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FTLP19 RNA expression–survival associations across cancer types. High FTLP19 expression shows unfavorable associations in UVM, KICH, CHOL, HNSC and BLCA, but favorable associations in LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for FTLP19 RNA expression.
This table summarizes FTLP19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in PAAD for RNA.
This table ranks reproducible tumor–normal expression differences for FTLP19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FTLP19 shows lower tumor expression in PAAD and LUSC and higher tumor expression in BLCA. The PAAD box plot shows higher FTLP19 RNA expression in normal versus tumor tissue (log2 FC = −0.240, t-test p = .006).
This table shows molecular features associated with FTLP19 in patient tissues and cancer cell lines. In patient samples, FTLP19 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
